Needham analyst David Saxon reiterated a Buy rating on CryoPort today and set a price target of $12.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Saxon has given his Buy rating due to a combination of factors including CryoPort’s impressive third-quarter revenue performance, which surpassed market expectations. The company’s success was largely driven by its Life Sciences Services segment, and management has subsequently increased its revenue guidance for 2025.
Additionally, there is potential for further revenue growth in 2026, as suggested by management’s commentary. CryoPort is also making strides towards achieving adjusted EBITDA profitability, with the possibility of reaching this milestone by the fourth quarter of 2025. These positive developments have led to an increased price target of $12, reinforcing the Buy rating.